1403766-87-9 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 3-Boc-3-azabicyclo[3.2.1]octane-8-carboxylate is used as a building block for the preparation of various pharmaceuticals and other biologically active molecules. Its unique structure and functional groups make it a valuable component in the synthesis of new drugs and therapeutic agents.
Used in Organic Synthesis:
Methyl 3-Boc-3-azabicyclo[3.2.1]octane-8-carboxylate is used as a versatile intermediate in organic synthesis, enabling the creation of a wide range of chemical compounds. Its Boc protecting group and methyl ester functionality contribute to its utility in various synthetic pathways.
Used in Asymmetric Synthesis:
Methyl 3-Boc-3-azabicyclo[3.2.1]octane-8-carboxylate is used as a chiral auxiliary in asymmetric synthesis, facilitating the production of enantiomerically pure compounds. This is particularly important in the development of pharmaceuticals, where the stereochemistry of a molecule can significantly impact its biological activity and safety.
Used in Drug Discovery and Development:
Methyl 3-Boc-3-azabicyclo[3.2.1]octane-8-carboxylate is used in drug discovery and development processes, where its unique properties and reactivity contribute to the identification and optimization of new drug candidates. Its applications in this field highlight its potential to advance the development of innovative therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1403766-87-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,3,7,6 and 6 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1403766-87:
(9*1)+(8*4)+(7*0)+(6*3)+(5*7)+(4*6)+(3*6)+(2*8)+(1*7)=159
159 % 10 = 9
So 1403766-87-9 is a valid CAS Registry Number.
1403766-87-9Relevant articles and documents
ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
-
Paragraph 0369; 0370, (2021/04/17)
A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.
